Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Operating Expenses (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Operating Expenses data on record, last reported at $159.6 million in Q4 2025.

  • For Q4 2025, Operating Expenses rose 75.76% year-over-year to $159.6 million; the TTM value through Dec 2025 reached $522.3 million, up 72.09%, while the annual FY2025 figure was $522.3 million, 72.09% up from the prior year.
  • Operating Expenses reached $159.6 million in Q4 2025 per TARS's latest filing, up from $133.2 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $159.6 million in Q4 2025 and bottomed at $14.7 million in Q2 2021.
  • Average Operating Expenses over 5 years is $57.2 million, with a median of $37.8 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: soared 972.62% in 2021, then dropped 11.7% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $14.8 million in 2021, then soared by 69.49% to $25.1 million in 2022, then soared by 129.54% to $57.5 million in 2023, then soared by 57.89% to $90.8 million in 2024, then skyrocketed by 75.76% to $159.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $159.6 million in Q4 2025, $133.2 million in Q3 2025, and $124.8 million in Q2 2025.